Vineet Gupta, director of Parabolic Drugs spoke to CNBC-TV18 about the latest with is company and the way ahead.
Parabolic Drugs is up nearly 6.3% today. Vineet Gupta, director of the company spoke to CNBC-TV18 about the latest happenings and the way ahead for pharma player.
Below is the edited transcript of the interview. Also watch the accompanying video.
Q: You non-Beta Lactum plant has recently got commissioned. Could you tell us what plans you have by way of molecule launches perhaps coming soon?
A: We are planning eight molecules to be launched in this current quarter and going on to FY13, and these are in therapeutic segments like ant-diabetes, anti-hypertension, dermatology and women healthcare. I would not like to take specific molecule names at this stage, but we have a total product pipeline of 17 molecules to be launched from this side over a three-year period, eight of which get launched in this year, and then the further ones get launched subsequently.
Q: Which geographies would you be focusing on with regard to the non-Beta Lactum space?
A: Non-Beta Lactum plant has been made as per US FDA guidelines, so we are looking at both regulated and unregulated markets. Keeping with our current portfolio where we supply to India; we supply to unregulated markets and we supply to regulated markets; so this plant is going to be pretty much in the same line. We are looking to serve across geographies.
Q: You had indicated earlier that the company is building a very strong pipeline in the CRAMS segment. Has there been any progress on that, any contracts which you have already signed or are under current negotiation?
A: There are six-seven large contracts under negotiation, but as on date, nothing has been signed. So at this moment, I cannot specifically tell you much.
Q: When you say large, could you give us a rough size of how big they could potentially be?
A: They could be in the range of USD 5 million per annum to about USD 15 million.
Q: You were in talks specifically with a Japanese firm for bulk supply deal. Is that still on?